齐心协力更好地治疗肝癌

StephenW

LIVER CANCER IN 2019
Joining the dots for better liver cancer treatment

    Lo-Kong Chan & Irene Oi-Lin Ng

Nature Reviews Gastroenterology & Hepatology volume 17, pages74–75(2020)Cite this article

    397 Accesses

    30 Altmetric

    Metrics details

In 2019, powerful single-cell analyses were applied to liver cancer biology at an unprecedented level. In parallel with this achievement was the identification of serum α-fetoprotein as a biomarker for patient selection in the use of ramucirumab for liver cancer and that β-catenin activation can distinguish between liver cancer immunotherapy responders and non-responders.
Key advances

    Powerful single-cell analyses discover rare cellular sub-populations and complex cell–cell interactions at an unprecedented level, which could help to solve key questions in liver biology and liver cancer2.

    The identification of serum α-fetoprotein levels as a biomarker for patient selection in the use of ramucirumab highlights the importance of patient stratification for better treatment outcomes6.

    Specific molecular mutations of hepatocellular carcinoma tumours such as β-catenin help to distinguish between immunotherapy responders and non-responders, as well as opening up new avenues for treatments9.
2019年肝癌
齐心协力更好地治疗肝癌

    陈罗刚＆吴ene琳

自然评论，胃肠病和肝病，第17卷，第74-75页（2020年）

    397次访问

    30高度

    指标详细信息

在2019年，功能强大的单细胞分析以前所未有的水平应用于肝癌生物学。与该成就同时进行的是鉴定血清α-甲胎蛋白作为雷莫昔单抗治疗肝癌的患者选择的生物标志物，β-catenin的激活可以区分肝癌免疫治疗应答者和非应答者。
关键进展

    强大的单细胞分析发现了前所未有的罕见细胞亚群和复杂的细胞间相互作用，这可能有助于解决肝脏生物学和肝癌中的关键问题2。

    血清α-甲胎蛋白水平的确定是在使用拉莫西单抗中选择患者的生物标志物，突显​​了将患者分层以改善治疗效果的重要性6。

    肝细胞癌肿瘤的特定分子突变（例如β-catenin）有助于区分免疫治疗反应者和非反应者，并为治疗开辟新途径9。